Christopher Borges

Title: Christopher Borges: Innovator in HPV-Specific Binding Molecules

Introduction

Christopher Borges is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules that target human papilloma virus (HPV). His innovative work has the potential to impact treatment methodologies for HPV-related conditions.

Latest Patents

Christopher Borges holds a patent for HPV-specific binding molecules. This patent includes binding molecules such as T-cell receptors (TCRs) and antibodies that specifically recognize or bind to HPV 16, including its E6 and E7 proteins. Additionally, the patent covers engineered cells containing these binding molecules, as well as compositions and methods of treatment involving their administration.

Career Highlights

Throughout his career, Borges has worked with prominent companies in the biotechnology sector. He has been associated with Juno Therapeutics GmbH and Editas Medicine, Inc., where he has contributed to advancing therapeutic solutions in the field of genetic medicine.

Collaborations

Some of his notable coworkers include Cameron Brandt and Brian J. Belmont, who have collaborated with him on various projects related to his innovative work.

Conclusion

Christopher Borges is a pioneering inventor whose work on HPV-specific binding molecules showcases his commitment to advancing medical science. His contributions are poised to make a significant impact in the treatment of HPV-related diseases.